Artificial Intelligence for Early Cancer Detection Leveraging Multi-Omics: A Comprehensive Review

Abstract

Early detection of cancer remains a major determinant of patient outcomes, with delays often leading to advanced disease and reduced survival. The integration of artificial intelligence (AI) with multi-omics data has emerged as a transformative approach, enabling clinicians to identify malignancies at their nascent stages. This review synthesizes current scientific evidence on AI-driven multi-omics platforms for early cancer detection, encompassing epidemiology, underlying mechanisms, risk stratification, clinical presentations, diagnostic paradigms, management strategies, recent advances, and guideline recommendations. The clinical implications and future directions are discussed to provide a comprehensive resource for healthcare professionals.

Introduction

Cancer continues to be a leading cause of mortality worldwide, with over 19 million new cases and 10 million deaths annually. Traditional diagnostic modalities, including imaging and histopathology, often identify cancer at advanced stages. Recent advances in high-throughput omics technologies - genomics, transcriptomics, proteomics, metabolomics, and epigenomics have revolutionized our understanding of tumorigenesis. The advent of AI, particularly machine learning (ML) and deep learning (DL), allows for the integration and analysis of vast, complex, multi-omic datasets, facilitating early detection with unprecedented precision. This review aims to provide clinicians with an evidence-based overview of how AI-driven multi-omics can transform early cancer detection and improve patient outcomes.

Epidemiology / Disease Burden

The global burden of cancer is escalating, with estimates predicting 28 million new cases annually by 2040. Early-stage detection remains suboptimal for many solid and hematological malignancies, contributing to poor prognosis. For example, five-year survival rates for localized breast and colorectal cancers exceed 90%, whereas late-stage diagnoses drop survival rates below 20%. The limitations of current screening protocols, such as mammography or colonoscopy, underscore the need for more sensitive, specific, and comprehensive strategies. Multi-omics approaches, when combined with AI, have demonstrated the potential to capture minute molecular alterations preceding overt clinical manifestations, offering a significant epidemiological advantage in cancer control efforts.

Pathophysiology

Cancer arises from the accumulation of genetic and epigenetic alterations that disrupt cellular homeostasis. Tumorigenesis involves a complex interplay among somatic mutations, aberrant gene expression, proteomic dysregulation, altered metabolic pathways, and epigenetic modifications. Multi-omics technologies provide a systems-level perspective, capturing the dynamic molecular landscape of early tumorigenesis. AI algorithms, particularly those employing ensemble learning and neural networks, can integrate heterogeneous omics layers to discern subtle signatures indicative of early malignant transformation. Mechanistically, this enables the identification of actionable biomarkers that might be missed by single-omic approaches, enhancing both sensitivity and specificity in early cancer detection.

Risk Factors

Traditional risk factors for cancer include age, family history, lifestyle factors (smoking, diet, alcohol), environmental exposures, and infectious agents. However, multi-omics analyses have refined risk stratification by uncovering individual-specific molecular susceptibilities, such as inherited gene mutations (e.g., BRCA1/2), somatic copy number variations, aberrant methylation patterns, and metabolomic perturbations. AI-driven models can assimilate and weigh these diverse data points, generating personalized risk profiles to inform targeted screening and prevention strategies. Integration of polygenic risk scores with environmental and clinical data further enhances risk prediction, enabling proactive surveillance in high-risk cohorts.

Clinical Features

Early-stage cancers are often asymptomatic or present with non-specific symptoms, complicating timely diagnosis. Multi-omics platforms, coupled with AI, enable the detection of molecular alterations in peripheral blood, urine, or other biofluids, often before clinical symptoms manifest. For example, circulating tumor DNA (ctDNA), exosomal RNA, and aberrant protein signatures can serve as early indicators, with AI models trained to recognize complex patterns associated with preclinical disease states. This approach facilitates the shift from symptom-based to biomarker-driven detection, potentially reducing diagnostic delays and improving clinical vigilance.

Diagnosis

Conventional diagnostic workflows rely heavily on imaging, histopathology, and limited biomarker assays, each with inherent sensitivities and specificities. AI-powered multi-omics diagnostics leverage supervised and unsupervised learning methods to integrate genomics, proteomics, transcriptomics, and metabolomics data, generating multidimensional signatures that can distinguish malignant from benign or healthy states. Recent studies report that AI-based multi-omics models achieve area under the receiver operating characteristic curve (AUC) values exceeding 0.95 for early detection of several malignancies, including lung, pancreatic, and ovarian cancers. Liquid biopsy approaches, enhanced by AI, are now capable of detecting minimal residual disease and early relapse, further refining diagnostic accuracy.

Treatment & Management

While the principal focus of AI-driven multi-omics has been early detection, these platforms also inform therapeutic decision-making. By characterizing tumor molecular heterogeneity, AI algorithms can identify actionable mutations, predict drug response, and guide personalized treatment regimens. This is particularly relevant in the era of precision oncology, where timely and accurate molecular profiling is critical for optimal outcomes. Furthermore, early detection via multi-omics allows for less aggressive interventions, reduced morbidity, and improved quality of life. Ongoing integration with electronic health records and clinical decision support systems is poised to streamline management pathways in real-world settings.

Recent Advances / Emerging Therapies

Recent years have seen rapid advancements in both omics technologies and AI methodologies. Ultra-deep sequencing, single-cell omics, and spatial transcriptomics provide unprecedented resolution of tumor biology. AI innovations including federated learning, explainable AI, and transfer learning improve model transparency and generalizability. Multi-center trials have validated AI-based multi-omics platforms for early detection of multiple cancer types, with several assays advancing to clinical implementation. Integration of multi-analyte liquid biopsies with AI has demonstrated high sensitivity in detecting early-stage cancers from asymptomatic individuals. These innovations are expected to drive the next wave of population-based screening initiatives.

Guideline Recommendations

Professional societies, such as the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO), are increasingly recognizing the value of multi-omics and AI in early cancer detection. While formal guidelines for routine clinical use are still evolving, consensus statements advocate for continued research, rigorous validation, and standardized reporting of AI-driven multi-omics studies. Clinicians are encouraged to participate in ongoing trials, contribute to real-world data registries, and integrate validated AI-omics tools into multidisciplinary care pathways where appropriate. Ethical considerations, including data privacy and algorithmic bias, must be proactively addressed as these technologies become embedded in clinical practice.

Conclusion

AI-powered multi-omics represents a paradigm shift in the early detection and management of cancer. By integrating diverse molecular data streams with advanced computational models, clinicians can achieve unprecedented accuracy in identifying malignancies at their most treatable stages. While challenges remain in terms of validation, standardization, and clinical integration, the convergence of AI and multi-omics holds immense promise for personalized oncology and cancer prevention. Ongoing collaboration between clinicians, data scientists, and regulatory bodies will be essential in realizing the full potential of this transformative approach.